Drug profile · INN
fostamatinib disodium
TAVALISSE
fostamatinib disodium (TAVALISSE) is a tyrosine-protein kinase syk inhibitor. Associated with RIGEL PHARMACEUTICALS INC. Route of administration: oral. Current US regulatory status: approved.
Drug details — fostamatinib disodium
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 20
- Programs
- 12
- Data quality
- 0.89
Quick answer
fostamatinib disodium (TAVALISSE) is a tyrosine-protein kinase syk inhibitor. Associated with RIGEL PHARMACEUTICALS INC. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Tyrosine-protein kinase SYK inhibitor
Primary target: Tyrosine-protein kinase SYK
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12043620
Benzazole compounds and methods for making and using the compounds
granted -
US 11939317
Amide compounds and method for making and using
granted -
US 11827628
Compositions and methods for inhibition of the JAK pathway
granted -
US 11667611
Compositions and methods for inhibition of the JAK pathway
granted -
US 11530194
Amide compounds and method for making and using
granted -
US 11524955
2,4-diamino-pyrimidine compounds and method for making and using the compounds
granted -
US 11370808
Pyrazole compounds and methods for making and using the compounds
granted -
US 11299486
Benzazole compounds and methods for making and using the compounds
granted -
US 11279686
Nrf2 activating compounds and uses thereof
granted -
US 11230554
Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
granted -
US 11220496
Compounds and method for treating autoimmune diseases
granted -
US 11198689
Compositions and methods for inhibition of the JAK pathway
granted -
US 11174251
Compositions and methods for inhibition of the JAK pathway
granted -
US 11174246
Direct AMPK activators
granted -
US 11129819
Fumarate analogs and uses thereof
granted -
US 11007193
2,4-pyrimidinediamine compounds and their uses
granted -
US 10947216
Amide compounds and method for making and using
granted -
US 10941135
Nrf2 activating compounds and uses thereof
granted -
US 10941134
AMPK-activating heterocyclic compounds and methods for using the same
granted -
US 10889562
Prodrugs of Nrf2 activating compounds and uses thereof
granted
Frequently asked questions
What is fostamatinib disodium?
fostamatinib disodium (TAVALISSE) is a tyrosine-protein kinase syk inhibitor. Associated with RIGEL PHARMACEUTICALS INC. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for fostamatinib disodium?
TAVALISSE is a marketed brand name for fostamatinib disodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of fostamatinib disodium?
fostamatinib disodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.